Developing effective antiviral treatments demands a rigorous testing process. At Chimerix, we use our broad chemical library—which houses more than 3,000 structurally diverse nucleotides—to tailor our therapies and build more potent antiviral therapeutics, as well as therapies for other disease states categorized by an unmet need for effective therapies.
Nucleoside analogs are widely used in antiviral therapy, and are ideally suited as potential antivirals for both DNA and RNA viruses that rely on viral encoded polymerases for their replication. We are currently screening the library against a broad spectrum of DNA and RNA viruses.
Where possible, we apply our lipid conjugate technology to build potent antivirals that are orally absorbed and have favorable tissue penetration.